Expecto Health Science, a Singapore-headquartered, Asia-focused clinical research organization (CRO), and Southern Star Research (SSR), a leading Australia-based CRO, announced a strategic investment-driven partnership.
The investment marks a significant milestone in Expecto Health Science’s long-term growth strategy, accelerating its ability to deliver seamless, end-to-end clinical trial execution across the Asia-Pacific region.
This alliance establishes a powerful cross-regional collaboration, enabling sponsors to transition efficiently from early-phase studies in Australia and New Zealand to late-phase clinical development programs across key Asian markets.
“This strategic investment reinforces our vision of building a leading Asia-Pacific CRO with deep regional expertise and global connectivity,” said Dr. Pramod Kashid, CEO of Expecto Health Science. “Southern Star Research brings strong early-phase capabilities and a proven track record of scientific rigor. Together, we are creating a scalable platform that enables sponsors to accelerate clinical development across the region.”
Southern Star Research CEO Lloyd Prescott added, “We have long admired Expecto’s operational excellence and regional footprint. This association reflects our confidence in their leadership and our shared ambition to expand high-quality clinical research capabilities throughout Asia-Pacific.”
Through this collaboration, both organizations enhance their ability to “follow the molecule” - enabling early-phase trials conducted in Australia and New Zealand to transition efficiently into Phase II and III programs across Singapore, Malaysia, India, South Korea, Taiwan, the Philippines, Thailand, and Indonesia.
Collectively, the two organizations now support clinical development programs across 10 countries, with nearly 200 professionals serving biotech and pharmaceutical sponsors globally.
Expecto Health Science will continue to operate as a Singapore-based, Asia-focused CRO, maintaining its existing leadership team.
The alliance will offer sponsors expanded clinical development capabilities across the Asia-Pacific region and globally through strategic partners and collaborators in Europe and the United States. A joint governance structure will ensure seamless delivery, operational integration, and enhanced value for sponsors.
The strategic investment takes effect in February 2026. Clients and partners can expect full continuity of service, along with the added benefits of broader expertise, deeper regional reach, and strengthened end-to-end capabilities.
Further updates regarding joint initiatives and growth plans will be shared in the coming months.
